Reflective Case-Based Oncology Collective: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Burst CME™ - Part I – Overview of Pathophysiology, Diagnosis, and Management of HER3 Expressing Cancers
View More
Burst CME™ - Part II – Advent of HER3 Targeted Approaches and Rationale in NSCLC Care
View More
Burst CME™ - Part III – Advent of HER3 Targeted Approaches and Rationale in Breast Cancer Care
View More
Medical Crossfire®: Clinical Decision-Making Under New Paradigms for HR+/HER2- Breast Cancer
View More
Advances In™: Meeting Unmet Clinical Needs in TNBC and HR+ Breast Cancer with TROP2-Targeted Regimens
View More
Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow
View More
Oncology Consultations®: Clinical Impact of HER2-Low Expressing Breast Cancer and Novel Targeted Therapies to Address Unmet Needs in Care
View More
Obe-cel Leads to Favorable Efficacy in R/R B-ALL With Varying Leukemic Burden
December 10th 2023Durable responses were seen with obecabtagene autoleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia across bone marrow blast levels, with best efficacy and tolerability in those with less than 5% blasts.
Auto-HCT Improves PFS, Relapse Rates in Relapsed LBCL Subset During Complete Response
December 10th 2023Compared with CAR T-cell therapy, autologous hematopoietic cell transplantation resulted in lower relapse rates and improved progression-free survival in patients with relapsed large B-cell lymphoma while they were in complete response.
Orca-T Demonstrates High RFS and OS in Intermediate/High-Risk MDS
Orca-T, an allogeneic hematopoietic cell transplant biologic designed to control alloreactive immune responses, led to less graft-vs-host disease and favorable overall survival and relapse-free survival in patients with intermediate- and high-risk myelodysplastic syndrome.
Study of Golidocitinib Finds Favorable Efficacy in Pretreated PTCL
The JAK1 inhibitor golidocitinib led to responses in the challenging disease setting of relapsed/refractory peripheral T-cell lymphoma, as well as manageable hematologic toxicity, in the phase 2 JACKPOT8 study.
Axi-cel Improves OS vs SOC in Older Patients With Large B-Cell Lymphoma
Results from the phase 3 ZUMA-7 trial showed superior progression-free survival and overall survival in patients 65 and older with large B-cell lymphoma with axicabtagene ciloleucel compared with standard of care.
Single and Dual-Target D8 CAR T Cells Show Tolerability, Efficacy in R/R MM
December 10th 2023Investigators in the MCARTY study reported safety and high response rates in a small number of patients with relapsed/refractory multiple myeloma who received chimeric antigen receptor T-cell therapy designed with a new process to target the D8 binder, meant to improve efficacy in targeting BCMA.
Pirtobrutinib Shows Durable Responses After Covalent BTKi Treatment in CLL/SLL
Updated results from the phase 1/2 BRUIN study show a high objective response rate and promising progression-free survival outcomes with pirtobrutinib following prior covalent Bruton tyrosine kinase inhibition in patients with chronic lymphocytic leukemia.
Outpatient CAR T-Cell Therapy Process Improved by Virtual Care Platform
December 10th 2023Four outpatient chimeric antigen receptor T-cell therapy programs utilized a virtual care program including remote patient monitoring following T-cell infusion, reducing hospital admissions and helping patients contact nurses during non-clinical hours.
Zanubrutinib Induces Sustained PFS Benefit in Relapsed/Refractory CLL/SLL
December 10th 2023According to extended follow-up of the phase 3 ALPINE trial, treatment with zanubrutinib continued to demonstrate improved progression-free survival in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Khan Discusses Third-Line Novel Treatment Approaches for R/R DLBCL
December 10th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Cyrus M. Khan, MD, and participants discussed the case of a patient with diffuse large B-cell lymphoma who progressed after complete remission on standard-of-care frontline therapy, then had stable disease after receiving polatuzumab vedotin, bendamustine, and rituximab.
Real-World Data Suggest Favorable Outcomes With Post-Axi-Cel Administration in R/R LBCL
December 10th 2023Although the use of bridging therapy prior to treatment with axicabtagene ciloleucel did not improve efficacy or safety outcomes for patients with relapsed/refractory large B-cell lymphoma, responses to bridging therapy may be prognostic of favorable outcomes after axi-cel administration.
An All-Oral Revumenib Combination Achieves 100% ORR Patients with R/R AML
Results from the phase 1/2 SAVE trial demonstrated an improved objective response rate when revumenib was added to decitabine/cedazuridine, and venetoclax for patients with relapsed/refractory acute myeloid leukemia.
Real-World Analysis Shows Similar Safety, Efficacy With Teclistamab in RRMM
December 9th 2023The retrospective analysis demonstrated comparable outcomes with teclistamab from the phase 2 MajesTEC-1 trial, highlighting the need for close monitoring and supportive care in patients treated for their relapsed or refractory multiple myeloma.
Neoadjuvant Nivolumab/Carboplatin/Paclitaxel Delivers High pCR Rates in Early-Stage TNBC
December 9th 2023Neoadjuvant nivolumab and non–anthracycline containing chemotherapy produced promising pathologic complete response rates regardless of whether nivolumab was administered before or during treatment with carboplatin and paclitaxel in patients with stage I to IIB triple-negative breast cancer.
Survival Benefit With Neoadjuvant Pembro/Chemo, Adjuvant Pembro Upheld in High-Risk Early TNBC
Neoadjuvant pembrolizumab combined with chemotherapy followed by adjuvant pembrolizumab compared with placebo plus chemotherapy continued to show a clinically meaningful improvement in event-free survival in patients with high-risk, early-stage triple-negative breast cancer.
Eradat Explores BTK Inhibitors for Relapsed/Refractory CLL After Frontline BCL-2 Therapy
December 9th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Herbert A. Eradat, MD, reviewed data supporting the use of zanubrutinib and acalabrutinib in treatment of relapsed/refractory chronic lymphocytic leukemia.